Norpen Oro (Olanzapine)

Olanzapine, the active ingredient in Norpen Oro, is an atypical antipsychotic presented as an oral tablet for oral use. It is used to treat schizophrenia and bipolar disorder in adult patients.

GNH USA supplies Norpen Oro as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Olanzapine is an atypical antipsychotic that modulates dopamine and serotonin pathways in several psychiatric conditions.

- Schizophrenia: reduces psychotic symptoms such as hallucinations and delusions. - Bipolar disorder: stabilises mood and diminishes manic episodes. - Schizoaffective disorder: improves both mood and psychotic features.

Olanzapine may cause a range of adverse reactions, from mild to serious.

Common Side Effects: - Weight gain: increased appetite and caloric intake. - Sedation: drowsiness or reduced alertness. - Dry mouth: reduced salivation. - Constipation: slowed gastrointestinal motility.

Serious or Rare Side Effects: - Neuroleptic malignant syndrome: life‑threatening reaction with fever and muscle rigidity. - Agranulocytosis: severe reduction in white blood cells. - Tardive dyskinesia: involuntary, repetitive movements.

Before initiating therapy, clinicians should consider several safety measures.

- Metabolic monitoring: regularly assess weight, glucose, and lipid levels. - Suicidal ideation: evaluate risk, especially during early treatment. - Liver function: check hepatic enzymes periodically. - Elderly patients: use caution in dementia‑related psychosis due to increased mortality risk. - Discontinuation: avoid abrupt cessation to reduce relapse risk. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Olanzapine can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid): - Carbamazepine: induces metabolism, lowering olanzapine levels. - Rifampin: strong enzyme inducer that reduces drug exposure. - Smoking: polycyclic aromatic hydrocarbons increase clearance.

Moderate Interactions (Monitor Closely): - Anticholinergics: may increase anticholinergic burden. - Antihypertensives: additive hypotensive effects. - Benzodiazepines: enhanced sedation when combined.